VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)
Launched by COLUMBIA UNIVERSITY · Jun 8, 2024
Trial Information
Current as of May 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a device called VibraCool, which uses vibrations and cooling to help reduce pain after surgery for an anterior cruciate ligament (ACL) reconstruction. The main goal is to see if using VibraCool can lessen pain and reduce the need for opioid medications, which are often prescribed after surgery. By doing this, researchers hope to improve recovery and reduce the side effects associated with opioid use.
To participate in this trial, you need to have recently undergone ACL reconstruction surgery. Unfortunately, children who have had a specific type of ACL surgery that often results in more pain, as well as individuals who do not speak English, cannot join this study. If you are eligible and decide to participate, you can expect to use the VibraCool device during your recovery period to help manage your pain. This trial is currently looking for volunteers, and your involvement could contribute valuable information to help others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Underwent ACL reconstruction
- Exclusion Criteria:
- • Pediatric iliotibial band ACL reconstruction (known to cause significantly more pain)
- • Non-english speakers (limitations of our study group)
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported